PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease.
AURORA, Colo.,...
Brown & Brown, Cintas Corporation, Haleon, Linde, Raia Drogasil and Veeva Systems are making access to health and hygiene more equitable.
EDINBURGH, Scotland, June...
LOUISVILLE, Ky., June 23, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a specialty pharmacy partner by Deciphera Pharmaceuticals, LLC for ROMVIMZA™ (vimseltinib), which has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.1 This indication was approved based on the Phase III MOTION study of ROMVIMZA in patients with tenosynovial giant cell tumor (TGCT).2
MIAMI, June 23, 2025 /PRNewswire/ -- The Miller School of Medicine and UHealth – University of Miami Health System welcome Juan Pablo Umaña, M.D., an...
ASPIRE pivotal Level-1 PMA IDE study evaluated PearlMatrix vs. local autograft in single-level TLIF procedures:- Demonstrated statistically superior fusion speed;- Achieved over twice as...
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient...
U.S. Dermatology Partners expands access to dermatology care in the Lake of the Ozarks region with the opening of its newest office.
OSAGE BEACH, Mo.,...
As if the insurance industry needed another reminder that it's universally adored, the titans of health coverage are slinking back from their beloved pastime...
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.
ASJ Open Forum Earns Second Consecutive Score, Signaling Steady Growth
GARDEN GROVE, Calif., June 20, 2025 /PRNewswire/ -- The Aesthetic Society is proud to announce a...
JEJU, South Korea, June 20, 2025 (GLOBE NEWSWIRE) -- Dr. Myung Ju Lee, MD, PhD, Chief Surgeon at VIP Plastic Surgery Clinic in Jeju, South Korea, a leading Korean plastic surgery clinic, presented groundbreaking research on facelift innovation at the International Society of Aesthetic Plastic Surgery (ISAPS) Olympiad World Congress, held June 18–21, 2025, at Marina Bay Sands, Singapore.
INRS Professor receives $1.2M to advance glioblastoma research
LAVAL, QC, June 20, 2025 /CNW/ - Professor Maya Saleh, a world-renowned expert in immuno-oncology at the Institut national...